BMEA Biomea Fusion, Inc.
Price Chart
Executive Summary
Biomea Fusion presented new clinical and translational data for icovamenib at ADA 2026, showing durable HbA1c improvements in type 2 diabetes and preserved C-peptide in type 1 diabetes without immune activation. The company also expanded its Phase I BMF-650 study to test a rapid titration schedule, with initial weight reduction data expected in Q3 2026. These are positive data readouts for a clinical-stage biotech, but no financial figures or guidance were provided.
Actionable Insight
The positive clinical data strengthen icovamenib's profile across both T1D and T2D, but the stock remains binary on future trial outcomes and regulatory milestones. Monitor the BMF-650 weight reduction data in Q3 2026 as a key catalyst for the GLP-1 program.
Key Facts
- Icovamenib showed a 1.8% placebo-adjusted HbA1c reduction at Week 52 in T2D patients on background GLP-1 RA therapy.
- In T1D patients diagnosed <3 years, 200 mg icovamenib increased C-peptide AUC by ~52% at Week 12 vs baseline; at Week 52, C-peptide remained ~7% below baseline vs ~47% annual decline in historical placebo.
- No evidence of systemic immune activation; inflammatory markers stable or reduced through Week 52.
- Phase I BMF-650 study expanded to evaluate rapid one-step titration; initial 28-day weight reduction data expected in Q3 2026.
- Translational data showed icovamenib enhanced GLP-1 expression, promoted myogenic effects in muscle cells, and induced browning/lipolysis in adipocytes.
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue.
Risk Factors
- Clinical-stage biotech with no approved products or revenue; high binary risk on future trial results.
- Icovamenib's C-peptide preservation at Week 52 was only ~7% below baseline, which may not be statistically significant vs placebo without a formal comparison.
- BMF-650 is in early Phase I; weight reduction data are preliminary and may not replicate in larger trials.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307662 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
Institutional Cluster
| $1.20 awaiting T+5 | awaiting T+5 | — | $1.17 (−2.50%) |
|
Jun 5, 2026
9d ago
|
Press Release
| $1.29 awaiting T+5 | awaiting T+5 | — | $1.17 (−9.30%) |
|
May 11, 2026
4w ago
|
8-K
| $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $1.17 (−25.95%) |
|
May 11, 2026
4w ago
|
Press Release
| $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $1.17 (−25.95%) |
|
Apr 28, 2026
6w ago
|
8-K
| $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $1.17 (−23.53%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $1.17 (−23.53%) |
|
Mar 31, 2026
10w ago
|
Press Release
| $1.53 $1.76 | ▲ +15.03% | ▲ +11.09% | $1.17 (−23.53%) |
|
Mar 24, 2026
11w ago
|
Press Release
| $1.22 $1.49 | ▲ +22.13% | ▲ +22.37% | $1.17 (−4.10%) |
|
Feb 25, 2026
15w ago
|
8-K
| $1.41 $1.39 | ▼ −1.42% | ▼ −0.32% | $1.17 (−17.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access